{"publication_id":"7ab156d6-8b98-4d64-9135-9b29624ec48e","content_hash":"sha256:f6507c1332db54d5eb4b55c11786d6ba3731963eadb00cb6154b874dac74bf16","nodes":[{"id":"7ab156d6-8b98-4d64-9135-9b29624ec48e","type":"publication","title":"Risk-Stratified Stroke Prevention with SGLT2 Inhibitors: A Meta-Analysis of ASCVD-Dependent Efficacy"},{"id":"claim_1","type":"claim","text":"The cited A/B receipts support a specific working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.84 [95% CI, 0.62-1.16]; P=0.29). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis."},{"id":"claim_2","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_3","type":"claim","text":"The stroke-prevention efficacy of SGLT2 inhibitors appears risk-stratified, diverging significantly between populations with established atherosclerotic cardiovascular disease (ASCVD) and those without, suggesting a need for precision-based therapeutic targeting beyond broad diabetic indications."},{"id":"claim_4","type":"claim","text":"`fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836"},{"id":"claim_5","type":"claim","text":"_No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._"},{"id":"source_1","type":"source","study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","year":2021,"doi":"10.1016/j.phrs.2021.105836","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_2","type":"source","study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","year":2023,"doi":"10.1161/jaha.123.030578","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_3","type":"source","study":"Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2","year":2020,"doi":"10.2215/cjn.10140620","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","year":2020,"doi":"10.1161/circulationaha.120.050391","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","year":2022,"doi":"10.1161/circulationaha.122.060511","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"}],"edges":[{"from":"7ab156d6-8b98-4d64-9135-9b29624ec48e","to":"claim_1","type":"contains_claim"},{"from":"7ab156d6-8b98-4d64-9135-9b29624ec48e","to":"claim_2","type":"contains_claim"},{"from":"7ab156d6-8b98-4d64-9135-9b29624ec48e","to":"claim_3","type":"contains_claim"},{"from":"7ab156d6-8b98-4d64-9135-9b29624ec48e","to":"claim_4","type":"contains_claim"},{"from":"7ab156d6-8b98-4d64-9135-9b29624ec48e","to":"claim_5","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}